Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 313 to 314 of 314 entries
Sorted by: Best Match Show Resources per page
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

The lancet. Diabetes & endocrinology

Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M.
PMID: 34861154
Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30.

BACKGROUND: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients...

Cite
Verma S, Dhingra NK, Butler J, et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2021;10(1):35-45doi: 10.1016/S2213-8587(21)00292-8.
Verma, S., Dhingra, N. K., Butler, J., Anker, S. D., Ferreira, J. P., Filippatos, G., Januzzi, J. L., Lam, C. S. P., Sattar, N., Peil, B., Nordaby, M., Brueckmann, M., Pocock, S. J., Zannad, F., Packer, M. (2022). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. The lancet. Diabetes & endocrinology, 10(1), 35-45. https://doi.org/10.1016/S2213-8587(21)00292-8
Verma, Subodh, et al. "Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial." The lancet. Diabetes & endocrinology vol. 10,1 (2022): 35-45. doi: https://doi.org/10.1016/S2213-8587(21)00292-8
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. PMID: 34861154.
Copy Download .nbib Format: NLM
Neutrophil Extracellular Traps and Interleukin 17 in Ankylosing Spondylitis.

Mediterranean journal of rheumatology

Papagoras C, Chrysanthopoulou A, Mitsios A, Tsironidou V, Ritis K.
PMID: 34447919
Mediterr J Rheumatol. 2021 Jun 30;32(2):182-185. doi: 10.31138/mjr.32.2.182. eCollection 2021 Jun.

Ankylosing spondylitis (AS) is a chronic inflammatory disease traditionally regarded as mediated by T lymphocytes. Recent progress has identified that cells of innate immunity are also important for the processes of inflammation and new bone formation, a hallmark of...

Cite
Papagoras C, Chrysanthopoulou A, Mitsios A, et al. Neutrophil Extracellular Traps and Interleukin 17 in Ankylosing Spondylitis. Mediterr J Rheumatol. 2021;32(2):182-185doi: 10.31138/mjr.32.2.182.
Papagoras, C., Chrysanthopoulou, A., Mitsios, A., Tsironidou, V., & Ritis, K. (2021). Neutrophil Extracellular Traps and Interleukin 17 in Ankylosing Spondylitis. Mediterranean journal of rheumatology, 32(2), 182-185. https://doi.org/10.31138/mjr.32.2.182
Papagoras, Charalampos, et al. "Neutrophil Extracellular Traps and Interleukin 17 in Ankylosing Spondylitis." Mediterranean journal of rheumatology vol. 32,2 (2021): 182-185. doi: https://doi.org/10.31138/mjr.32.2.182
Papagoras C, Chrysanthopoulou A, Mitsios A, Tsironidou V, Ritis K. Neutrophil Extracellular Traps and Interleukin 17 in Ankylosing Spondylitis. Mediterr J Rheumatol. 2021 Jun 30;32(2):182-185. doi: 10.31138/mjr.32.2.182. eCollection 2021 Jun. PMID: 34447919; PMCID: PMC8369274.
Copy Download .nbib Format: NLM
Showing 313 to 314 of 314 entries